Welcome to our dedicated page for Inspire Medical Systems news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical Systems stock.
Inspire Medical Systems develops and commercializes minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. Its proprietary Inspire therapy is approved by the FDA, EU MDR and PDMA for moderate to severe obstructive sleep apnea, and product updates include the Inspire V system.
Company news commonly covers quarterly and annual results, revenue guidance, cash flow, earnings measures, reimbursement and coding developments, product launch activity, regulatory clearances such as MRI compatibility, executive changes and healthcare conference presentations.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 20, 2024, at 7:30 a.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replays available for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems has initiated a $75 million accelerated share repurchase (ASR) program with Goldman Sachs, as part of its previously announced $150 million share repurchase authorization. The ASR transaction is scheduled to conclude in Q1 2025. The company's decision reflects confidence in its long-term growth potential, supported by strong revenue and earnings growth. The broader repurchase program, set to expire on August 5, 2026, allows for flexible implementation through various transaction methods and can be modified or discontinued at the company's discretion.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 20, 2024, at 11:00 a.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replay availability for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems reported strong Q3 2024 financial results with revenue of $203.2 million, up 33% year-over-year. The company achieved a gross margin of 84.1% and generated operating income of $14.3 million. Earnings per share reached $0.60, compared to a loss of $0.29 in the prior year period.
The company activated 66 new U.S. centers and created 13 new sales territories, bringing totals to 1,371 centers and 323 territories. Based on strong performance, Inspire raised its full-year 2024 revenue guidance to $793-798 million and increased EPS guidance to $1.20-1.40.
Inspire Medical Systems (NYSE: INSP) announced its upcoming participation in the UBS Global Healthcare Conference. The medical technology company, which specializes in minimally invasive solutions for obstructive sleep apnea, will present on Wednesday, November 13, 2024, at 11:00 a.m. Eastern Time.
The presentation will be available through a live webcast, with replay access remaining available for two weeks afterward in the Event Archive section of Inspire's Investor website.
Inspire Medical Systems, Inc. (NYSE: INSP) has announced it will release its third quarter 2024 financial results after the market closes on Monday, November 4, 2024. The company's management team will host a conference call at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
Investors can access the earnings call webcast through the Investor Relations page of Inspire's website or via a provided link. Those planning to ask questions during the call should register using a separate link. Registration is recommended at least 10 minutes before the call starts. A replay of the call will be available on the company's Investor Relations website approximately two hours after the event and will be archived for two weeks.
Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in two upcoming investor conferences. The company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:00 a.m. Eastern Time and the Wells Fargo 2024 Healthcare Conference at 3:00 p.m. Eastern Time, both on September 4, 2024.
Both presentations will be accessible via live webcasts, with links provided for each event. Replays of the presentations will be available for two weeks following the events in the Event Archive section of Inspire's Investor website at https://investors.inspiresleep.com.
Inspire Medical Systems, Inc. (NYSE: INSP) reported strong Q2 2024 financial results, with revenue growing 30% year-over-year to $195.9 million. The company achieved a gross margin of 84.8% and generated $5.1 million in operating income. Earnings per share reached $0.32. Inspire activated 81 new U.S. centers and created 12 new sales territories. The company received CE Mark Certification under EU MDR, countrywide reimbursement in France, and FDA approval for the Inspire V neurostimulation system. Based on strong performance, Inspire increased its full-year 2024 revenue guidance to $788-$798 million (26-28% growth) and raised EPS guidance to $0.60-$0.80.
Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company specializing in innovative solutions for obstructive sleep apnea (OSA), has announced its first-ever share repurchase program. The company's Board of Directors has authorized the repurchase of up to $150.0 million of outstanding common stock, set to expire on August 5, 2026.
CEO Tim Herbert highlighted the company's significant progress toward sustained profitability and strong revenue growth in Q2. The repurchase program reflects Inspire's financial strength and belief in its growth prospects, particularly following the recent FDA approval of the Inspire V therapy system. The company views its stock as undervalued and considers the repurchase an attractive investment opportunity.
Inspire Medical Systems, Inc. (NYSE: INSP) has received FDA approval for its Inspire V therapy system, a next-generation neurostimulator for treating obstructive sleep apnea (OSA). The system includes a new neurostimulator, Bluetooth® patient remote, and physician programmer. This approval is a significant milestone for Inspire therapy's future. The company is focusing on operational readiness, including product manufacturing and inventory buildup. Inspire plans a soft launch in late 2024 and a full launch in 2025 for the U.S. market. This advancement reinforces Inspire's commitment to developing innovative, minimally invasive solutions for OSA patients.